Sight Sciences, Inc.

Sight Sciences, Inc.

SGHTยทNASDAQ

$4.55

+4.8%
HealthcareMedical - Devices

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

At a Glance

Live Snapshot
Market Cap$247.57M
EPS-0.7400
P/E Ratio-6.15
Earnings Date08/06/2026
3Y-61.0%
5Y-8.0%
10Y+105.0%
3Y-77.0%
5Y-76.0%
10Y-61.0%
3Y+44.0%
5Y-98.0%
10Y-85.0%
SGHT

Sight Sciences, Inc. Cash Conversion Engine

SGHT ยท NASDAQ
Net Income-38.43M
Depreciation & Amortization487.00K
Stock-Based Compensation13.05M
Change in Working Capital-6.39M
Others1.59M
Capital Expenditures-224.00K
Free Cash Flow-29.92M

Cash Flow Quality Analysis

FCF Conversion Rate

77.9%

Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.

CapEx Intensity

-0.8%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

-31.6%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

-$6.39M

Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.

Cash Flow Quality Insight

Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.

Sight Sciences, Inc. Cash Flow Statement

SGHT โ€ข NASDAQ

Sight Sciences, Inc. Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
OPERATING ACTIVITIES
-38.4M
-51.5M
-55.5M
-86.2M
-63M
-34.7M
-25.9M
-14.3M
487K
712K
614K
710K
632K
554K
295K
63K
0.0
0.0
0.0
0.0
7.8M
0.0
138K
0.0
13.1M
17.1M
14.6M
13M
5.1M
497K
118K
52K
1.6M
2.4M
2.3M
2.3M
1.3M
684K
662K
58K
-6.4M
9M
-9.1M
-5.7M
-4.3M
784K
-341K
-358K
-29.7M
-22.4M
-47.2M
-76M
-52.5M
-32.2M
-25M
-14.5M
INVESTING ACTIVITIES
-224K
-385K
-791K
-970K
-813K
-953K
-672K
-570K
-224K
-385K
-791K
-970K
-813K
-953K
-672K
-570K
FINANCING ACTIVITIES
1.8M
1.1M
1.3M
1.2M
256.7M
0.0
0.0
0.0
0.0
4.2M
0.0
0.0
0.0
20.5M
14M
0.0
-58K
-261K
-224K
0.0
-4.2M
-154K
-2.1M
-23K
1.8M
5M
1.1M
1.2M
252.5M
73.4M
42.7M
12.2M
CASH FLOW SUMMARY
-28.1M
-17.8M
-46.9M
-75.7M
199.2M
40.3M
17M
-2.8M
120.4M
138.1M
185M
260.7M
61.5M
21.2M
4.2M
7.1M
92.2M
120.4M
138.1M
185M
260.7M
61.5M
21.2M
4.2M
-29.9M
-22.7M
-48M
-76.9M
-53.4M
-33.1M
-25.7M
-15M

SEC Filings

SGHT - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
10-Q

10-Q 2026 Q1

Q1

May 06, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 06, 2026
May 06, 2026
2026
8-K

8-K 2026

N/A

April 23, 2026
April 22, 2026
2026
DEF 14A

DEF 14A 2026

N/A

April 22, 2026
June 04, 2026
2026
8-K

8-K 2026

N/A

March 30, 2026
March 27, 2026
2026
10-K

10-K 2025 FY

FY

March 04, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

March 04, 2026
March 04, 2026
2026
8-K

8-K 2026

N/A

February 03, 2026
January 29, 2026
2026
8-K

8-K 2026

N/A

January 13, 2026
January 13, 2026
2026
10-Q

10-Q 2025 Q3

Q3

November 06, 2025
September 30, 2025
2025
Showing 1 to 10 of 93 filings